Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

1(14%)

Results Posted

100%(3 trials)

Terminated

1(14%)

Phase Distribution

Ph phase_1

29%

Ph phase_4

14%

Ph not_applicable

57%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

2(28.6%)

Phase 4Post-market surveillance

1(14.3%)

N/ANon-phased studies

4(57.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(3)

Terminated(1)

Other(1)

Detailed Status

Completed3

Recruiting1

unknown1

Terminated1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (28.6%)

Phase 41 (14.3%)

N/A4 (57.1%)

Trials by Status

recruiting114%

unknown114%

terminated114%

not_yet_recruiting114%

completed343%

Recent Activity

1 active trials

Showing 5 of 7

terminatedphase_4

Clinical Trials (7)

Showing 7 of 7 trials

NCT03738878Phase 4

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

Terminated

NCT06959004Not Applicable

Substance P-Induced Migraine Attacks Without Aura

Recruiting

NCT04676763Not Applicable

Substance P Challenge in Healthy Participants

Completed

NCT06632080Not Applicable

Effects of Substance P on Headache Induction in Healthy Individuals

Not Yet Recruiting

NCT02820558Phase 1

Neuropeptide Therapy of Recent Onset Type 1 Diabetes

Unknown

NCT01280149Phase 1

Reduction of IgE Antibody in Human Allergic Subjects

Completed

NCT01413542Not Applicable

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7